表紙
市場調査レポート

インドの有効成分 (API) 市場の機会

Opportunities in Indian API Market

発行 RNCOS E-Services Pvt. Ltd. 商品コード 341900
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
インドの有効成分 (API) 市場の機会 Opportunities in Indian API Market
出版日: 2015年10月01日 ページ情報: 英文 75 Pages
概要

インドは、アジア太平洋地域で第3位の有効成分 (API) 市場です。政府のさまざまな取り組みによって、今後数年間で有望な成長を示す可能性があります。インドのAPI市場は、2014年〜2020年のCAGRで、13%の成長が予測されています。

当レポートでは、インドのAPI市場について調査分析し、市場の潜在性と将来の成長機会、主要促進要因と課題、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 インドのAPI産業の見通し

  • 主要な5市場
  • インドのシェア
  • インドの市場規模
  • 主要なAPI

第4章 促進要因と課題

  • 促進要因
  • 課題

第5章 市場区分

  • 製造の種類別
  • 薬剤の種類別
  • APIの種類別
  • 治療分野の種類別

第6章 合併と買収

第7章 政府の取り組み

第8章 規制シナリオ

第9章 競合情勢

  • プロファイル
    • Sun Pharma
    • Cipla Limited
    • Biocon
    • Dr. Reddy's Laboratorie
    • Lupin Ltd.
    • Aurobindo Pharma Limited
    • Wockhardt
    • Zydus Cadila
    • Glenmark
    • Jubilant LifeSciences

第10章 将来の見通し

第11章 機会と提言

図表

目次

India, being the third largest API market in the Asia-Pacific region, has been gaining a lot of attention worldwide since the last few years. The accelerated growth of the Indian API market can be attributed to the increased efforts being made by the Indian government to improve the infrastructure of the API industry and provide maximum support to domestic API manufacturers. This is being done, so that India does not have to depend on other countries for the import of APIs. Indian API manufacturers are also trying to strengthen their hold of the regulated markets by various means. A major competitor for India in this field is China, which provides APIs at very low rates. However, all the hard work being put in by the API manufacturers and government will help India to become the top API market not only in Asia-Pacific, but also in the world.

In the report "Opportunities in Indian API Market", RNCOS analysts have addressed the current scenario of the Indian API market, major drivers of the market, and factors hindering the growth of the market. Apart from this, the segmentation of the market by various parameters, such as type of manufacture, type of drug, type of API and type of therapeutic area, has also been specified. The important mergers and acquisitions in the Indian API market have also been mentioned in the report. Various initiatives taken by the government to promote the Indian API industry have been listed down. Owing to the various government initiatives, such as the declaration of 2015 as the "Year of APIs", "Make in India" campaign, etc., the Indian API market is likely to show a promising growth in the coming years. The Indian API market is forecasted to grow at a CAGR of 13% from 2014-2020.

The report also mentions the key players in the Indian API Market. For every player, a brief business overview, geographic revenue break up, and segment wise revenue break up has been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. A separate section has been provided in the report for the opportunities and recommendations for the development of the Indian API market. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Indian API market.

Table of Contents

1. Analyst View

2. Research Methodology

3. India API Industry Outlook

  • 3.1 Top 5 API Markets of the World
  • 3.2 Share of India in Global API Market
  • 3.3 Indian API Market Size (2009-2014)
  • 3.4 Top 10 APIs in the Indian API Market

4. Drivers & Challenges

  • 4.1 Drivers
    • 4.1.1 Rising Healthcare Expenditure
    • 4.1.2 Increasing Disposable Incomes
    • 4.1.3 Rise in Geriatric Population
    • 4.1.4 Increasing Incidences of Chronic Diseases
    • 4.1.5 Patent Expiry of Blockbuster Drugs
    • 4.1.6 Increased Consumption of Generic Drugs
    • 4.1.7 Invention of New Generation of APIs
  • 4.2 Challenges
    • 4.2.1 Overdependence on China for Imports
    • 4.2.2 Complex License Renewal Procedure
    • 4.2.3 Few Manufacturers in the API Industry
    • 4.2.4 Inadequate Infrastructure Facilities
    • 4.2.5 Lack of Government Support
    • 4.2.6 Stringent Regulatory Policies

5. Market Segmentation

  • 5.1 By Type of Manufacturing
  • 5.2 By Type of Drug
  • 5.3 By Type of API
  • 5.4 By Type of Therapeutic Area

6. Mergers and Acquisitions

7. Government Initiatives

  • 7.1 Katoch Committee
  • 7.2 'Make in India' Campaign
  • 7.3 Pharma Vision 2020
  • 7.4 Establishment of New NIPERs

8. Regulatory Scenario

9. Competitive Landscape

  • 9.1 Profiles
    • 9.1.1 Sun Pharma
    • 9.1.2 Cipla Limited
    • 9.1.3 Biocon
    • 9.1.4 Dr. Reddy's Laboratories
    • 9.1.5 Lupin Ltd.
    • 9.1.6 Aurobindo Pharma Limited
    • 9.1.7 Wockhardt
    • 9.1.8 Zydus Cadila
    • 9.1.9 Glenmark
    • 9.1.10 Jubilant LifeSciences

10. Future Outlook

11. Opportunities and Recommendations

List of Figures:

  • Figure 3-1: India API Market Trade (%), 2009-2014
  • Figure 3-2: Top 5 API Markets of the World (%), 2014
  • Figure 3-3: Share of India in Global API Market (%), 2014
  • Figure 3-4: India API Market (Billion US$), 2009-2014
  • Figure 4-1: Healthcare Expenditure (% of GDP), 2009-2014
  • Figure 4-2: Personal Disposable Income (Billion US$), 2009-2014
  • Figure 4-3: Population Above 65 years (Million), 2009-2014
  • Figure 4-4: Diabetes Population in the Age Group 20-79 years (Million), 2013 & 2030
  • Figure 4-5: Number of Cancer Cases ('000), 2014 & 2020
  • Figure 5-1: Share of Captive and Merchant Market APIs in Indian API Market (%), 2014
  • Figure 5-2: Share of Branded and Generic Drug APIs in Indian API Market (%), 2014
  • Figure 5-3: Share of Chemical/Small Molecule and Biotech APIs in Indian API Market (%), 2014
  • Figure 5-4: Share of APIs by their Application in Therapeutic Areas in Indian API Market (%), 2014
  • Figure 8-1: API License Procedure
  • Figure 9-1: Sun Pharma- Break up of Revenue by Therapeutic Segment (%), 2014
  • Figure 9-2: Sun Pharma- Break up of Revenue by Geography (%), 2014
  • Figure 9-3: Cipla Limited-Break up of Revenue by Geography (%), 2014
  • Figure 9-4: Biocon-Break up of Revenue by Geography (%), 2014
  • Figure 9-5: Dr. Reddy's Laboratories - Break up of Revenue by Geography (%), 2014
  • Figure 9-6: Lupin Limited- Revenues by Trade (Billion US$), 2014
  • Figure 9-7: Aurobindo Pharma Limited - Break up of Revenue of Formulations by Geography (%), 2014
  • Figure 9-8: Wockhardt- Break up of Revenue by Geography (%), 2014
  • Figure 9-9: Zydus Cadila- Break up of Revenue by Geography (%), 2014
  • Figure 9-10: Glenmark- Break up of Revenue by Geography (%), 2014
  • Figure 9-11: Jubilant LifeSciences- Break up of Revenue by Geography (%), 2014
  • Figure 10-1: Indian API Market (Billion US$), 2015-2020

List of Tables:

  • Table 3-1: Top 10 APIs in the Indian API Market (2014)
  • Table 4-1: List of Blockbuster Drugs Losing Patent (2015-2020)
  • Table 4-2: API Import from China (2011-2015)
  • Table 6 1: Mergers and Acquisitions in Indian Pharma Industry (2014-2015)
  • Table 9-1: Sun Pharma- Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 9-2: Biocon-Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 9-3: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 9-4: Lupin Limited- Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 9-5: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 9-6: Wockhardt- Revenue by Business Segment (Billion US$), 2013 & 2014
  • Table 9-7: Zydus Cadila- Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 9-8: Glenmark- Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 9-9: Jubilant LifeSciences- Revenues by Business Segment (Billion US$), 2013 & 2014
Back to Top